The importance of tumor versus immune cell PD-L1 expression in predicting benefit to PD-1 pathway blockade in NSCLC, and the role of PD-L1 regulators as potential contributors to these outcomes are poorly understood. The gene discussed is RPL17; the disease is neoplasm.